Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

HemCon Medical Technologies, Inc. ("HemCon"), an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd. ("Zeria"), a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.

“This partnership will also give HemCon the opportunity to break into the Asian market, which has not been the company's focus until now, and represents a significant opportunity to help provide unique solutions for patient safety and wound care in Japan.”

HemCon's product offerings include a full line of hemostatic dressings with antibacterial properties. The technology, originally developed for use on the battlefield to control severe hemorrhaging, is now used in acute care settings worldwide for bleeding control, wound management, and infection prevention. The HemCon line also includes an over-the-counter line of hemostatic products, as well as a revolutionary oral wound care dressing for oral surgery and periodontal procedures.

Zeria, established in 1955 and listed on the Tokyo Stock Exchange, has a wide-ranging portfolio that includes hemostatic surgical compounds, which the HemCon products will augment. Zeria holds a strong position in the gastroenterology (GI) field and markets products in dermatology and cardiovascular disease. The company also markets a range of consumer healthcare products and medications.

Zeria's partnership with HemCon will allow them to strategically expand their product offering and market reach in the wound care, surgery, oral care, and patient safety markets. "Zeria will be establishing a separate division to specifically manage the HemCon product line as a new pillar in Zeria's business," said Zeria President and CEO Sachiaki Ibe.

"HemCon is proud to be partnering with Zeria, one of the most well-balanced operating companies in the Japanese health care arena, to bring our advanced wound care products to the Japanese market," said HemCon CEO John W. Morgan. "This partnership will also give HemCon the opportunity to break into the Asian market, which has not been the company's focus until now, and represents a significant opportunity to help provide unique solutions for patient safety and wound care in Japan."

SOURCE HemCon Medical Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
White blood cell type identified as important contributor to inflammation in obesity